Will Plus Therapeutics stock go up?

According to Danelfin AI, Plus Therapeutics has today an AI Score of 2/10 (Strong Sell rating), because its probability of beating the market in 3 months (40.87%) is -9.96% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Plus Therapeutics stock?

The Plus Therapeutics target price is $4 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Plus Therapeutics stock right now?

Plus Therapeutics has today a Strong Sell rating (AI Score 2/10), according to Danelfin AI. Its probability of beating the market in 3 months (40.87%) is -9.96% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Plus Therapeutics stock is a good buy .

Is Plus Therapeutics undervalued right now?

Based on analysts, the average price target downside for Plus Therapeutics is 0.00% (1Y). According to Danelfin AI, Plus Therapeutics has today an AI Score of 2/10 (Strong Sell Rating).

What was the price range of Plus Therapeutics stock over the past 12 months?

The Plus Therapeutics stock price range over the past 12 months has been $2.92 - $22.24.

What is going on with Plus Therapeutics stock in the last 3 months?

The Plus Therapeutics stock performance in the last quarter has been +2.69%.

Does Plus Therapeutics offer dividend payments?

No, Plus Therapeutics does not currently pay dividends.

What is the current market capitalization of Plus Therapeutics?

Plus Therapeutics's market cap is $27.39M, as of 2026-07-03 08:00.

Plus Therapeutics Inc (PSTV) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

PSTV AI-Powered Stock Analysis

AI Score Explanation

AI Score

Strong Sell

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Plus Therapeutics Inc today receives an AI Score of 2/10, which translates to a Sell rating. The stock has a 41% probability of outperforming the market in the next 3 months, which is 10% lower than the average probability of any stock (51%). The top positive contributor is the Chart Pattern (180d), which boosts the probability by +1.67%. Additionally, Alpha 1Y (risk-adjusted return over the past year) adds +0.92%, Performance (YTD) adds +0.63%, and Distance from KAMA (20d) adds +0.58%. On the negative side, the strongest detractors include ATR (180d Volatility) (detracting -1.33%), Sloan Ratio (-1.32%), Beginning Cash (Millions) (-1.22%), Maximum Volatility (-1.07%), and Chart Pattern (504d) (-1.05%). Other notable detractors are Fear & Greed Index (CNN) (-1.01%), Analyst Lowest Price Upside (-1.00%), Gross Margin (-0.87%), and the Biotechnology industry (-0.68%). Notable data points include the stock's ATR (180d Volatility) in the top 10% (very high volatility), which historically detracts from performance. The Sloan Ratio is also in the top 10%, indicating high accruals and potentially lower earnings quality. Beginning Cash (Millions) is in the bottom 20% (low cash reserves), and Analyst Lowest Price Upside is in the bottom 10% (most bearish analyst outlook). On the positive side, Alpha 1Y is in the bottom 20% (negative alpha), yet it still contributes positively, suggesting the model sees potential mean reversion. Performance (YTD) is in the bottom 10% (poor year-to-date performance), also contributing positively. Overall, the stock faces significant headwinds from high volatility, weak earnings quality, and low cash reserves, resulting in a low AI Score and a Sell rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Momentum+0.49%
Direction and strength of recent price movements
Growth+0.33%
Expected pace of revenue and earnings expansion

Volatility-2.39%
How much the stock price tends to fluctuate
Sentiment-2.14%
How analysts and the market view the stock
Earnings Quality-1.70%
Stability and reliability of reported earnings
Valuation-1.61%
How the stock is priced relative to its fundamentals
Size & Liquidity-1.22%
Company size and trading liquidity
Profitability-0.87%
Profitability and operating efficiency metrics
Financial Strength-0.86%
Balance sheet strength and financial resilience

PSTV probability advantage of beating the market (3M):

-9.96%

AI Score

Strong Sell

Plus Therapeutics (PSTV) has an AI Score of 2/10 (Strong Sell) because, according to an overall analysis, it has a probability advantage of -9.96% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of PSTV (40.87%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
PSTV probability advantage of beating the market (3M)-9.96%
PSTV probability of beating the market (3M)40.87%

PSTV probability advantage of beating the market (3M): -9.96%

The AI-powered overall analysis of Plus Therapeutics (PSTV) is based on the 28 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of PSTV:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Technical	Chart Pattern (180d)	figure_21	N/A	+1.67%
Technical	ATR (180d Volatility)	690.79		-1.33%
Fundamental	Sloan Ratio	0.39		-1.32%
Fundamental	Beginning Cash (Millions)	8.76		-1.22%
Technical	Maximum Volatility	8.59%		-1.07%
Technical	Chart Pattern (504d)	figure_27	N/A	-1.05%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-1.01%
Sentiment	Analyst Lowest Price Upside	-0.78%	N/A	-1.00%
Technical	Alpha 1Y	-0.69%		+0.92%
Fundamental	Gross Margin	100		-0.87%
Fundamental	Upgrade to unlock			-0.86%
Fundamental	Upgrade to unlock			-0.70%
Sentiment	Upgrade to unlock			-0.68%
Fundamental	Upgrade to unlock			-0.66%
Technical	Upgrade to unlock			+0.63%

Rest of Alpha Signals: -1.40%

PSTV probability advantage of beating the market (3M)Total:-9.96%
PSTV AI Score

Significant changes Vs previous day

PSTV Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$4
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

PSTV Proven Sell Signal & Price Forecast

This is the price chart for PSTV from January 2, 2026 until today. The chart indicates, in red, the 90 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

PSTV Average Past Performance & Loss Rate

Three months after its 1359 Sell signals since July 2026, PSTV had an average performance of xxxxxxx and a xxxxxx Loss rate (negative performance).

1359 Past PSTV Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-57.59%
Average Alpha				-69.67%
Loss Rate (% Negative Perf.)				91.73%
% Negative Alpha				96.84%

PSTV Frequently Asked Questions

Will Plus Therapeutics stock go up?
According to Danelfin AI, Plus Therapeutics has today an AI Score of 2/10 (Strong Sell rating), because its probability of beating the market in 3 months (40.87%) is -9.96% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Plus Therapeutics stock?
Is it a good time to buy, sell, or hold Plus Therapeutics stock right now?
Is Plus Therapeutics undervalued right now?
What was the price range of Plus Therapeutics stock over the past 12 months?
What is going on with Plus Therapeutics stock in the last 3 months?
Does Plus Therapeutics offer dividend payments?
What is the current market capitalization of Plus Therapeutics?

Plus Therapeutics Inc Company Profile

In the arena of clinical-stage pharmaceutical development, Plus Therapeutics, Inc. has carved out a niche with its focus on creating, manufacturing, and delivering treatments catered to cancer patients. This innovative venture is anchored by its leading radiotherapeutic drug candidate, rhenium (186Re) obisbemeda - an exclusive radiotherapy treatment adept at targeting central nervous system cancers including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

Plus Therapeutics further augments its portfolio with the development of Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere. Designed as an intra-arterial injectable solution, this treatment targets multiple solid organ cancers; from primary to secondary liver cancers.

Underpinning its position in the market, Plus Therapeutics harnesses strategic partnerships and license agreements with entities such as NanoTx Corp., and The University of Texas Health Science Center based in San Antonio.

Once known as Cytori Therapeutics Inc., this dynamic organization embraced a fresh identity as Plus Therapeutics Inc. back in July 2019 – a nod towards the evolution of their mission and values. With roots dating back to 1996 and headquarters nestled in Austin, Texas; Plus Therapeutics continues to contribute significantly toward reversing the global impact of cancer.

Sector:Health Care
Country:United States
Industry:Biotechnology
Address:4200 Marathon Blvd., Suite 200, Austin
Employees:21
Website:plustherapeutics.com

Pros

Intellectual property protection for novel drug candidates

Addressing high unmet medical needs in oncology

Potential for premium pricing post-market approval

High switching costs for adopted therapeutic protocols

Platform technology applicability across multiple indications

Cons

Elevated clinical trial attrition rates

Substantial capital intensity for drug development

Uncertainty and duration of regulatory approval processes

Competition from established pharmaceutical pipelines

Specialized isotope supply chain vulnerabilities

Company	AI Score	Compare
RADXRadiopharm Theranostics Ltd
CNSPCNS Pharmaceuticals Inc
BYSIBeyondspring Inc
RNTXRein Therapeutics Inc
CATXPerspective Therapeutics Inc

Company	AI Score	Compare
RADXRadiopharm Theranostics Ltd
CNSPCNS Pharmaceuticals Inc
BYSIBeyondspring Inc
RNTXRein Therapeutics Inc
CATXPerspective Therapeutics Inc

PSTV Stock AI Analysis High Risk